Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Theravance Biopharma, Inc.

TBPH ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: N/A

Last Close

$17.03

▲ +0.00%

Market Cap $884.18M · Vol 6.08M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$884.18M

Small Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

40.00

Momentum

Beta

0.19

vs Market

52W High

$21.00

18.90% below

52W Low

$13.08

30.20% above

Volume

6.08M

Avg 444.97K

P/B

3.22

Price-to-book

ROE

N/A

Return on equity

Free Float

95.39%

Public shares

Shariah Compliance8 STANDARDS

✗ Theravance Biopharma, Inc. (TBPH) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TBPH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+0.12%

+0.35%

+15.46%

YTD

-8.98%

+21.04%

+80.40%

+140.20%

Financials & Valuation

TTM · Annual

Total Revenue	$107.46M
Net Income	$105.90M
Revenue Growth (YoY)	-20.86%
Gross Margin	100.00%
Operating Margin	-3.35%
Net Profit Margin	98.54%
ROE	N/A
ROA · ROIC	30.78% · 40.31%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	0.03
P/S	8.97
P/B	3.22
P/FCF	4.04
EPS Growth	N/A
Outstanding Shares	51.92M

Technical Indicators

50-Day SMA	$16.96
200-Day SMA	$17.18
RSI (14)	40.00
Beta	0.19
52-Week High	$21.00
52-Week Low	$13.08

Volume Today	6.08M
Avg Daily Volume (30D)	444.97K
Relative Volume	13.67x
Volatility (10D)	1.86
Volatility (30D)	2.36
Free Float	95.39%

Analyst Consensus

N/A

Current Price $17.03

Mean Target N/A

52W Low$13.08 52W High$21.00

Current

Target

$13.08 $21.00

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG004HK6YY0

ISINKYG8807B1068

CountryCayman Islands

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LLY Eli Lilly and Company +3.19% JNJ Johnson & Johnson -0.73% ABBV AbbVie Inc. +1.41% NVS Novartis AG -0.19% NOVN.S Novartis AG +1.12%

Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.